Nexstim
Pilot studies lift off in depression and painNexstim
Mapping out the 2020-24 corporate strategyNexstim
€2.3m rights issue is 273% subscribedNexstim
Hitting the right spotNexstim
€2.3m rights issue to progress both NBS and NBTNexstim
Patient registry shows promising outcomes in MDDNexstim
Focussing on strategic prioritiesNexstim
Licensing discussions with academic centre endNexstim
Making an impression in depressionNexstim
Warrants to be topped up with share placement